Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
11 Aug 2022
Small molecular drug
Aqilion has initiated its ARIA-1 phase 1 clinical safety trial assessing AQ280 – its drug candidate involved in the company’s Regulus development programme – on healthy volunteers.
AQ280 is a super selective Janus kinase 1 (JAK1) small molecule inhibitor that is under development for indications in the chronic inflammatory disease area.
The ARIA-1 trial has 64 healthy volunteers and will investigate potential side effects and pharmacokinetics. The trial is a dose escalation study, with the primary aim of determining the tolerability and safety of the drug candidate. This will be assessed in stages: one group will get a single ascending dose and another group will get a repeated oral dosage over several days as a multiple ascending dose.
The study is being conducted in the UK with the approval of the Medicines and Healthcare Products Regulatory Agency (MHRA) and findings from the ARIA-1 clinical trial are expected to be shared in mid-2023.
Sarah Fredriksson, chief executive officer of Aqilion, said: “Taking the step from preclinical to clinical development is an incredibly important milestone for everyone involved. [We now have] a pipeline with an innovative profile and a clear focus within chronic inflammatory diseases, including programmes from discovery to early clinical development.”
The Regulus programme is focused on developing a next-generation JAK1 inhibitor and Aqilion will start by testing, assessing and developing the drug candidate AQ280 as a potential treatment for eosinophilic oesophagitis (EoE).
EoE is a rare, chronic inflammatory disease of the oesophagus – also known as ‘allergic oesophagitis’ – and its main symptom among patients is swallowing difficulties. EoE is a relatively new diagnosis that is increasing in incidence. The disease is triggered by food allergens and both children and adults can be affected.
Upon completion of the ARIA-1 trial, Aqilion plans to apply for drug testing ahead of the phase 2a study in patients.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.